Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Foundation Medicine, Inc ., a precision medicine company transforming lives in cancer care and beyond, today announced that the company and its research collaborators will present 11 abstracts ...

Listen to more stories on the Noa app. This article was featured in the One Story to Read Today newsletter. Sign up for it here. President Donald Trump recently ordered his attorney general to ...

PredicineCARE, a urine-based test, is under FDA review as a companion diagnostic for bladder cancer, building on previous data and biomarker insights. PredicineCARE, a urine next-generation sequencing ...

Amgen's bemarituzumab trial has taken a turn, with a final analysis showing weaker survival benefits than previously found in an earlier pre-specified interim analysis. In June, Amgen and China ...

WASHINGTON, DC—On Wednesday at the American Chemical Society Fall 2025 meeting, students and seasoned drug hunters alike gathered in a spacious third-floor ballroom of the Walter E. Washington ...

Prognostic impact of histological subtypes in non-muscle-invasive UTUC: Propensity matched analysis. Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab ...

Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the company to lay off one-third of its staff and pivot to a combination of two ...

All products featured on Vogue are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. It almost feels ...